New hope for Tough-to-Treat neuroendocrine cancers as trial tests promising drug
NCT ID NCT04412629
Summary
This study is testing whether the drug cabozantinib can help control aggressive neuroendocrine tumors that have returned after initial treatment. The trial involves 35 adults whose cancer has progressed despite previous therapies. Researchers will measure whether tumors shrink, how long patients live without their cancer worsening, and monitor side effects to determine if this approach offers a better option for this difficult-to-treat condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE NEUROENDOCRINE NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.